Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naive or anti-TNF-exposed Crohn's disease: a multicenter cohort study.

ABSTRACT:

Background

Ustekinumab and vedolizumab are both effective for treating Crohn's disease (CD). However, no head-to-head trials have been conducted thus far. We aimed to compare the effectiveness of ustekinumab and vedolizumab in CD patients either naïve or exposed to tumor necrosis factor-alpha inhibitors (TNFi).

Methods

Patients treated with vedolizumab or ustekinumab for luminal CD were included from six centers in China from May 2020 to July 2023. Steroid-free remission, clinical remission, objective response, and remission at Weeks 26 and 52 were evaluated in a retrospective multicenter propensity score-weighted cohort.

Findings

A total of 536 patients were included (386 ustekinumab, and 150 vedolizumab). After adjustment, ustekinumab showed higher rates of clinical

SUBMITTER: Yang H 

PROVIDER: S-EPMC10711459 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature